182 related articles for article (PubMed ID: 28194436)
21. Histiocytic neoplasm subtypes differ in their MAP2K1 mutational type.
Emile JF; Hélias-Rodzewicz Z; Durham BH; Héritier S; da Silva M; Younas K; Cohen-Aubart F; Abdel-Wahab O; Diamond EL; Donadieu J; Haroche J
Blood Adv; 2023 Dec; 7(23):7254-7257. PubMed ID: 37878806
[TBL] [Abstract][Full Text] [Related]
22. Specific blood monocyte distribution in histiocytoses correlates with vascular involvement and disease activity.
Razanamahery J; Samson M; Guy J; Racine J; Row C; Greigert H; Nicolas B; Francois S; Emile JF; Cohen-Aubart F; Audia S; Haroche J; Bonnotte B
Haematologica; 2023 Dec; 108(12):3444-3448. PubMed ID: 37317872
[No Abstract] [Full Text] [Related]
23. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells.
Durham BH; Roos-Weil D; Baillou C; Cohen-Aubart F; Yoshimi A; Miyara M; Papo M; Hélias-Rodzewicz Z; Terrones N; Ozkaya N; Dogan A; Rampal R; Urbain F; Le Fèvre L; Diamond EL; Park CY; Papo T; Charlotte F; Gorochov G; Taly V; Bernard OA; Amoura Z; Abdel-Wahab O; Lemoine FM; Haroche J; Emile JF
Blood; 2017 Jul; 130(2):176-180. PubMed ID: 28566492
[TBL] [Abstract][Full Text] [Related]
24. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.
Milne P; Bigley V; Bacon CM; Néel A; McGovern N; Bomken S; Haniffa M; Diamond EL; Durham BH; Visser J; Hunt D; Gunawardena H; Macheta M; McClain KL; Allen C; Abdel-Wahab O; Collin M
Blood; 2017 Jul; 130(2):167-175. PubMed ID: 28512190
[TBL] [Abstract][Full Text] [Related]
25. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis.
Ballester LY; Cantu MD; Lim KPH; Sarabia SF; Ferguson LS; Renee Webb C; Allen CE; McClain KL; Mohila CA; Punia JN; Roy A; López-Terrada DH; John Hicks M; Fisher KE
Hematol Oncol; 2018 Feb; 36(1):307-315. PubMed ID: 28219109
[TBL] [Abstract][Full Text] [Related]
26. Histiocytoses: emerging neoplasia behind inflammation.
Haroche J; Cohen-Aubart F; Rollins BJ; Donadieu J; Charlotte F; Idbaih A; Vaglio A; Abdel-Wahab O; Emile JF; Amoura Z
Lancet Oncol; 2017 Feb; 18(2):e113-e125. PubMed ID: 28214412
[TBL] [Abstract][Full Text] [Related]
27. Circulating cell-free BRAF
Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease.
Goyal G; Shah MV; Call TG; Litzow MR; Hogan WJ; Go RS
JAMA Oncol; 2017 Sep; 3(9):1253-1256. PubMed ID: 28253394
[TBL] [Abstract][Full Text] [Related]
29. A cytologic diagnosis of BRAF
Chasseur P; Kyriakopoulou M; Vokaer B; Beukinga I; Casado Arroyo R; Cogan E; Couturier B
Acta Clin Belg; 2017 Oct; 72(5):369-371. PubMed ID: 28222655
[TBL] [Abstract][Full Text] [Related]
30. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
[TBL] [Abstract][Full Text] [Related]
31. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.
Durham BH; Lopez Rodrigo E; Picarsic J; Abramson D; Rotemberg V; De Munck S; Pannecoucke E; Lu SX; Pastore A; Yoshimi A; Mandelker D; Ceyhan-Birsoy O; Ulaner GA; Walsh M; Yabe M; Petrova-Drus K; Arcila ME; Ladanyi M; Solit DB; Berger MF; Hyman DM; Lacouture ME; Erickson C; Saganty R; Ki M; Dunkel IJ; Santa-María López V; Mora J; Haroche J; Emile JF; Decaux O; Geissmann F; Savvides SN; Drilon A; Diamond EL; Abdel-Wahab O
Nat Med; 2019 Dec; 25(12):1839-1842. PubMed ID: 31768065
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of MEK inhibition in patients with histiocytic neoplasms.
Diamond EL; Durham BH; Ulaner GA; Drill E; Buthorn J; Ki M; Bitner L; Cho H; Young RJ; Francis JH; Rampal R; Lacouture M; Brody LA; Ozkaya N; Dogan A; Rosen N; Iasonos A; Abdel-Wahab O; Hyman DM
Nature; 2019 Mar; 567(7749):521-524. PubMed ID: 30867592
[TBL] [Abstract][Full Text] [Related]
33. The coming of age of Langerhans cell histiocytosis.
Allen CE; Beverley PCL; Collin M; Diamond EL; Egeler RM; Ginhoux F; Glass C; Minkov M; Rollins BJ; van Halteren A
Nat Immunol; 2020 Jan; 21(1):1-7. PubMed ID: 31831887
[No Abstract] [Full Text] [Related]
34. Clinical responses and persistent
Eckstein OS; Visser J; Rodriguez-Galindo C; Allen CE;
Blood; 2019 Apr; 133(15):1691-1694. PubMed ID: 30718231
[No Abstract] [Full Text] [Related]
35. Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.
Jacobsen E; Shanmugam V; Jagannathan J
N Engl J Med; 2017 Dec; 377(24):2398-2399. PubMed ID: 29236635
[No Abstract] [Full Text] [Related]
36. Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.
Messinger YH; Bostrom BC; Olson DR; Gossai NP; Miller LH; Richards MK
Pediatr Blood Cancer; 2020 Dec; 67(12):e28712. PubMed ID: 32991018
[TBL] [Abstract][Full Text] [Related]
37. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.
Abla O; Jacobsen E; Picarsic J; Krenova Z; Jaffe R; Emile JF; Durham BH; Braier J; Charlotte F; Donadieu J; Cohen-Aubart F; Rodriguez-Galindo C; Allen C; Whitlock JA; Weitzman S; McClain KL; Haroche J; Diamond EL
Blood; 2018 Jun; 131(26):2877-2890. PubMed ID: 29720485
[TBL] [Abstract][Full Text] [Related]
38. Langerhans cell histiocytosis.
Rodriguez-Galindo C; Allen CE
Blood; 2020 Apr; 135(16):1319-1331. PubMed ID: 32106306
[TBL] [Abstract][Full Text] [Related]
39. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
[TBL] [Abstract][Full Text] [Related]
40. High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy.
Lee LH; Krupski C; Clark J; Wunderlich M; Lorsbach RB; Grimley MS; Burwinkel M; Nelson A; Kumar AR
Blood Adv; 2020 Feb; 4(4):717-727. PubMed ID: 32092141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
